Biocompatibles adds technology platform and two licences
This article was originally published in Clinica
Biocompatibles, a darling of the UK stock market since its entry into the stent market late last year, has added a new technology platform and two new licences to its own coatings know-how based on phosphorylcholine (PC). Together with its 1996 results, it also reported that it launched its DivYsio stent in selected markets in February. The company's shares doubled since its share issue last November, closing at £10.90 on March 26th.
You may also be interested in...
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.
The funding will be used to support clinical and preclinical development at its portfolio companies, with 8-10 programs in the clinic in 2021.